Advancing Animal Health Through Science and Innovation
At MEVAC, innovation is at the heart of everything we do. Our Research & Development program is built on a clear mission: anticipating emerging disease challenges and delivering scientifically advanced solutions that protect animal health, support food security, and strengthen livestock productivity worldwide.
We combine cutting-edge biotechnology with deep field expertise to develop vaccines tailored to the evolving needs of poultry, ruminant, and aquaculture industries.
MEVAC has developed a comprehensive vaccine value chain that connects scientific discovery with commercial impact. This model ensures continuous innovation while maintaining the highest standards of product quality and market relevance.
Public and private partnerships focused on pathogen isolation, genomic characterization, vaccine design, and advanced adjuvant technologies.
State-of-the-art manufacturing facilities that transform scientific innovation into scalable, high-quality vaccine solutions.
Collaboration with industry partners, regulatory authorities, advocacy groups, and governmental organizations to accelerate market access and support animal health advancement.
Continuous field monitoring and pathogen surveillance programs that generate real-world data, measure vaccine impact, and guide future innovation.
For more than 15 Years, MEVAC has continuously delivered pioneering vaccine technologies and first-in-market solutions across Africa, the Middle East, and global markets.
A breakthrough combined vaccine providing protection against Avian Influenza H5 and Newcastle Disease.
First organization in MENA and Africa to develop Reverse Genetics (RG) technology targeting the emerging H5N8 Clade 2.3.4.4b virus.
Recognized by GIZ and the Ministry of Industry for outstanding vaccine innovation following five years of intensive R&D efforts.
Introduction of an innovative Lumpy Skin Disease vaccine utilizing unique cell-line production technology and expertise.
Development of customized Foot-and-Mouth Disease vaccines targeting key African serotypes.
First worldwide reassorted H5N1 and multivalent Newcastle Disease vaccine platform.
The first hexavalent vaccine combining protection against HPAI, LPAI, and Newcastle Disease strains.
Development of MEVAC’s proprietary IMA Adjuvant technology.
Introduction of Rinnovac™ Eli-7 with ND Genotype VII technology.
Isolation and development of tetravalent Adenovirus (IBH) vaccines for breeders.
Isolation and development of trivalent REO vaccines for breeders.
Isolation and development of bivalent Gumboro (IBD) vaccines for breeders containing both classical and variant (A2B1) IBD strains.
2026–2030
MEVAC has a long-term innovation roadmap designed to accelerate the development of future animal health technologies and expand our global footprint to over 90 countries.
Key focus areas include:
Recombinant vaccine technology platforms with single, double, and triple inserts.
mRNA vaccine proof-of-concept programs for influenza applications.
Advanced immune-complex technologies.
Next-generation oil adjuvant systems.
Precision molecular vaccine customization for rapidly evolving field strains.